TC BioPharm CEO, Bryan Kobel, is Featured on The Stock Day Podcast
| TCBP Stock | USD 0.60 0.04 6.25% |
Slightly above 64% of TC BioPharm's investor base is looking to short. The analysis of the overall investor sentiment regarding TC BioPharm Holdings suggests that many traders are alarmed. TC BioPharm's investing sentiment overview a quick insight into current market opportunities from investing in TC BioPharm Holdings. Many technical investors use TC BioPharm Holdings stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
TCBP |
Phoenix, Arizona - The Stock Day Podcast welcomed TC BioPharm Holdings, PLC. , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. CEO of the Company, Bryan Kobel, joined Stock Day host Kevin Davis. Davis began the interview by asking about the Companys background and curr
Read at finance.yahoo.com
 |
TC BioPharm Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards TC BioPharm can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
TC BioPharm Fundamental Analysis
We analyze TC BioPharm's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TC BioPharm using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TC BioPharm based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
TC BioPharm is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
TC BioPharm Holdings Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with TC BioPharm stock to make a market-neutral strategy. Peer analysis of TC BioPharm could also be used in its relative valuation, which is a method of valuing TC BioPharm by comparing valuation metrics with similar companies.
Peers
TC BioPharm Related Equities
| BDRX | Biodexa Pharmaceticals | 14.00 | ||||
| IMMX | Immix Biopharma | 7.11 | ||||
| PHIO | Phio Pharmaceuticals | 3.03 | ||||
| RNAZ | Transcode Therapeutics | 2.94 | ||||
| QNRX | Quoin Pharmaceuticals | 1.69 | ||||
| ZURA | Zura Bio | 1.67 | ||||
| PALI | Palisade Bio | 1.65 | ||||
| UNCY | Unicycive Therapeutics | 1.47 | ||||
| REVB | Revelation Biosciences | 1.33 | ||||
| ALLR | Allarity Therapeutics | 0.90 | ||||
| ICU | LMF Acquisition | 1.57 | ||||
| SONN | Sonnet Biotherapeutics | 2.28 | ||||
| ZVSA | ZyVersa Therapeutics | 3.60 | ||||
| VRAX | Virax Biolabs | 4.83 |
Additional Tools for TCBP Stock Analysis
When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.